Invivyd (IVVD) announced positive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd’s novel monoclonal antibody candidate designed to be a superior alternative to COVID-19 ...
Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...
Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week treatment period and additional long-term follow-up of its ...
It began with a radio documentary about the paranormal, became a podcast that became a phenomenon, then a stage show and, now, "Uncanny" season 2 returns after a successful debut season on the BBC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results